Evidence map›Paper›PMID 38330012›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

The structure of a

Audra A Hargett, Hugo F Azurmendi, Conor J Crawford, Maggie P Wear, Stefan Oscarson, Arturo Casadevall, Darón I Freedberg

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Molecular Architecture ofbioRxiv : the preprint server for biology · 2026
    Article
  2. mBio · 2025
    Article
  3. Article
  4. Automated Synthesis of Algal Fucoidan Oligosaccharides.Journal of the American Chemical Society · 2024
    Article
  5. Article
  6. A consensus structural motif for the capsular polysaccharide ofProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  7. Article
  8. Semi-synthetic glycoconjugate vaccine candidate againstbioRxiv : the preprint server for biology · 2024
    Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Audra A Hargett *Laboratory of Bacterial Polysaccharides, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993.ORCID 0000-0002-0459-1392
Hugo F Azurmendi *Laboratory of Bacterial Polysaccharides, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993.ORCID 0000-0002-5773-9127
Conor J CrawfordW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205.
Maggie P WearW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205.
Stefan OscarsonCentre for Synthesis and Chemical Biology, University College Dublin, Dublin 4, Ireland.ORCID 0000-0002-8273-4918
Arturo CasadevallW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205.ORCID 0000-0002-9402-9167
Darón I FreedbergLaboratory of Bacterial Polysaccharides, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993.ORCID 0000-0003-1991-5174
Center for Biologics Evaluation and Research · USJohns Hopkins University · USUniversity College Dublin · IE

Funding

Synergy of Host Defense Mechanisms in the LungR01HL059842 · NHLBI · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1997 to 2023
$7.4M
Biology of Fungal MelaninR01AI052733 · NIAID · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 2003 to 2019
$6.6M
Conjugate vaccines for prevention and treatment of cryptococcosis - COVID-19 Revision SupplementR01AI152078 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CASADEVALL, ARTURO · 2020 to 2024
$5.1M
Exploiting antibody catalysis for treating CryptococcosisR01AI162381 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CASADEVALL, ARTURO · 2021 to 2025
$3.7M
NHLBI NIH HHS R01 HL059842NIAID NIH HHS R01 AI052733NIAID NIH HHS R01 AI152078NIAID NIH HHS R01 AI162381
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CryptococcosisCryptococcus neoformansAntibodies, FungalAntibodies, MonoclonalHumansMagnetic Resonance SpectroscopyMannansPolysaccharidesAntibodies, FungalAntibodies, MonoclonalMannansPolysaccharidescapsulecryptococcusMD simulationsNMRpolysaccharide

Identifiers

PMID38330012
PMCPMC10873606
OpenAlexW4391641105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.